✦ LIBER ✦

Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: A pilot series

✍ Scribed by Patrice Chevallier; Arnaud Pigneux; Nelly Robillard; Sameh Ayari; Thierry Guillaume; Jacques Delaunay; Marion Eveillard; Pierre-Yves Dumas; Eric Lippert; Mohamad Mohty; Thibaut Leguay

Book ID: 113773612
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 321 KB
Volume: 36
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2011.11.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Addition of rituximab to hyper-CVAD in t

Addition of rituximab to hyper-CVAD in the treatment of CD20-positive adult acute lymphocytic leukemia (ALL)

✍ A. Cumpston; R. Weisenborn; S. Ericson 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Rituximab plus ASHAP for the treatment o

Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma: a single-centre study of 20 patients

✍ Semra Aydin; Ulrich Dührsen; Holger Nückel 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 125 KB

Efficacy and Safety of Rituximab Combine

Efficacy and Safety of Rituximab Combined with ESHAP Chemotherapy for the Treatment of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

✍ Harting, Rekha; Venugopal, Parameswaran; Gregory, Stephanie A.; O'Brien, Teresa; 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 168 KB

Combination of ibrutinib with rituximab,

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

✍ Younes, Anas; Thieblemont, Catherine; Morschhauser, Franck; Flinn, Ian; Friedber 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 305 KB

Bendamustine as salvage treatment for pa

Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience

✍ A. García-noblejas; C. Martínez Chamorro; B. Navarro Matilla; C. Da Silva Rodrig 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 344 KB

Phase II study of elsamitrucin (BMY-2809

Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma

✍ S. L. Allen; L. P. Schacter; S. M. Lichtman; R. Bukowski; D. Fusco; M. Hensley; 📂 Article 📅 1996 🏛 Springer US 🌐 English ⚖ 351 KB